Several studies focused on NOR-1 as an essential gene targeted by miRNAs that controls pulmonary artery VSMC hyperplasia such as miR-638 [81], miR-508-3p [82] or miR-106b-5p [83], highlight this NR as a promising therapeutic target for the design of pharmacological strategies in pulmonary arterial hypertension and acute pulmonary embolism. The gene discussed is NR4A3; the disease is pulmonary arterial hypertension.